7月23日，截至港股收盘，恒生指数上涨1.62%，报25538.07点。瑞丽医美（02135.HK）收报0.125港元/ 股，上涨9.65%，成交量103万股，成交额12.42万港元，振幅12.28%。 最近一个月来，瑞丽医美累计跌幅10.24%，今年来累计涨幅6.54%，跑输恒生指数25.27%的涨幅。 财务数据显示，截至2024年12月31日，瑞丽医美实现营业总收入1.99亿元，同比增长5.26%；归母净利 润-5921.2万元，同比减少82.43%；毛利率35.82%，资产负债率61.78%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-1.96倍，行业中值1.36倍。瑞丽医美 市盈率-0.99倍，行业排名第101位；其他巨星医疗控股（02393.HK）为0.33倍、京玖康疗（00648.HK） 为0.38倍、医汇集团（08161.HK）为2.35倍、瑞慈医疗（01526.HK）为5.3倍、环球医疗（02666.HK） 为5.38倍。 资料显示，瑞丽医美国际控股有限公司('瑞丽医美'或'公司',连同附属公司统称'集团'),是中国浙江省 ...

Group 1 - Recently, Huai'an Puxin Enterprise Management Consulting Partnership (Limited Partnership) was established with a registered capital of 495 million yuan [1] - The business scope includes enterprise management consulting and investment activities using self-owned funds [1] - The enterprise is co-funded by Shenwan Hongyuan and others [1]

Core Insights - The business landscape in 2025 is characterized by unprecedented complexity, with a sluggish global economic recovery and accelerated domestic industrial upgrades, leading to a critical focus on effective high-end talent management as a key differentiator for corporate survival and elimination [1] Group 1: Talent Management Challenges - Companies face a paradoxical mindset of both "desiring talent" and "fearing talent," which manifests in three typical dilemmas [2] - The first dilemma is the fear of "losing control," where excessive management layers stifle creativity, resulting in a "workplace paralysis" that drives talent to competitors [2] - The second dilemma involves the fear of "questioning," where the suppression of expertise by seniority hinders organizational evolution, leading to a conservative decision-making path [3] - The third dilemma is the fear of "trial and error," where short-term risk aversion prevents companies from seizing market opportunities, resulting in the rejection of innovative proposals [4] Group 2: Solutions for Talent Management - To address these challenges, companies are increasingly recognizing the need to leverage professional services to reconstruct their talent management systems [5] - The approach taken by Southern Xinhua can be summarized in three steps: diagnosis, matching, and empowerment [7] - The first step involves a comprehensive diagnosis to identify the root causes of talent management issues, moving beyond superficial solutions to provide a detailed analysis of organizational culture and structure [7] - The second step focuses on precise matching of talent to organizational needs, utilizing a vast talent pool and a specialized team to ensure high compatibility between candidates and company requirements [9] - The third step emphasizes management empowerment, helping companies build a trust-based ecosystem with talent through tailored consulting services that drive performance and profitability [11] Group 3: Conclusion on Talent Competitiveness - In a competitive business environment, the ability to effectively utilize and manage talent is increasingly seen as a fundamental competitive advantage [13] - Companies that can overcome the fear associated with talent management and establish a trust relationship with their workforce are better positioned to thrive in a rapidly changing market [13] - Southern Xinhua's experience demonstrates that talent is no longer viewed as a cost but as a core asset driving growth, highlighting the importance of innovative talent management strategies [13]

简历显示，阮光寅:男,中国国籍,1963年出生,无永久境外居留权。曾任浙江山下湖珍珠有限公司销售 员、销售部经理、副总裁。现任本公司董事、浙江山下湖控股股份有限公司董事。 深交所公开信息显示，6月10日，创新医疗董事阮光寅在竞价交易公司股票，减持股数0.10万股，成交 均价11.67元，变动金额1.17万元，变动后持股数为191.99万股。 截至最新收盘，创新医疗总市值为49.11亿元。 创新医疗的主营范围包括，医院管理咨询服务,实业投资,医疗器械、医药产品的研发及技术咨询,医疗企 业管理咨询服务,健康管理咨询服务(不含诊疗业务),经营进出口业务(范围详见《中华人民共和国进出口 企业资格证书》)。(依法须经批准的项目,经相关部门批准后方可开展经营活动) 来源：金融界 从主营业务构成来看，截至2024年12月31日，公司医疗服务业务收入8.12亿元，占比99.52%，其他(补 充)收入387.85万元，占比0.48%。 创新医疗股东高管增减持详情如下： 日期变动人变动股数成交均价变动金额(万)变动原因变动后持股数变动人与董监高的关系2025-06-10阮 光寅-1000.0011.67-1.17竞价交易191. ...

上周跟几个大佬做了交流，大概是比我高一个层次的存在，他们要么创业成功（至少有12个月现金流）、要么财务自由，总之对市场的理解上会比我深刻很 多。 在他们眼里，我属于比较上进的后辈，所以多多少少会有些提携，在知道我有找工作的意向后，也有人抛出了橄榄枝…… 闲聊几句后，几个大佬其实很好奇：明明我在医疗AI领域积累很深，为什么选了AI+管理这么个赛道。这里的缘由也很简单，之前有一年的竞业协议与保密 条款。 而因为他们手里都有公司，于是最终的话题还是回到了管理本身，其中有个大佬想讨教我，于是问了一个问题：你觉得管理，是管人重要还是管事重要？ 管人还是管事？ 其实这个问题，去年我是有比较完善的答案的： 所谓管事，就是保证这个事情的目标或过程是正确的；所谓管人，就是保证这件正确的事，有正确的人在做。 再进一步，所谓管人，就是保证这个做事的人，他的状态是没问题的。 而从人性上说，越是重要的事，我们喜欢交给越是信任的人，而如果这个信任的人状态出问题了，那么就会变得很麻烦，组织执行力的核心其实是个比较经 典的杨三角： 所以在今年之前，我是更倾向于管事的，因为人这个东西可变因子太多，他十分不受控，管事进一步衍生就是各种机制、流程 ...

Core Viewpoint - Three companies submitted IPO applications to the SEC, with two from China seeking to list on NASDAQ, indicating a trend of Chinese firms entering the U.S. capital markets [1]. Company Summaries 1. Xin Cheng - Xin Cheng Consulting Limited, under Thrive Capital Group Co., Ltd, filed for an IPO with the ticker symbol EFTY, aiming to raise between $5.6 million and $8.4 million by offering 1.4 million shares at a price range of $4 to $6 per share [2][3]. - The company, headquartered in Hong Kong, provides comprehensive investor relations services, including public relations management and due diligence [3]. - Financial performance shows revenue growth from $630,000 in 2023 to $2.53 million in 2024, with net income increasing from $32,696 to $852,499 in the same period [3]. - The ownership structure indicates that Kit Shing Cheung holds 94.94% of the shares prior to the IPO [7]. 2. Hang Feng International - Hang Feng International Asset Management Limited, under Hang Feng Technology Innovation Co., Ltd, also filed for an IPO with the proposed ticker FOFO, seeking to raise $5.5 million by offering 1.38 million shares at $4 each [8][9]. - The company is based in Hong Kong and operates primarily in corporate management consulting and asset management services [9]. - Financial data reveals a revenue increase from $119,534 in 2023 to $2.03 million in 2024, with a turnaround in net income from a loss of $919,173 to a profit of $866,769 [10]. - Qian Fenglei holds 75.61% of the shares before the IPO [15].

内部人事透露：京东健康、哇哈哈、修正、国美、王老吉等国内知名公司都是公司合作的对象。截止到 2025年4月，杭州快招无忧企业管理有限公司总人数已经超过了140人的规模。 本轮融资的资金将被主要用于加强快招无忧国内竞争力，以进一步提升服务质量和效率。同时，资金还 将用于市场拓展，加速在全国范围内的业务布局，以及加强品牌建设，提升"快招无忧"的市场影响力。 此外，还将利用这笔资金吸引更多的行业顶尖人才，专业团队，为公司持续创新和发展提供坚实的人才 保障。 杭州快招无忧企业管理有限公司2025年A轮融资成功公告 杭州快招无忧企业管理有限公司在2025年3月底成功完成了A轮融资，融资总额达到人民币1000万元， 此次投资由某知名投资机构独家领投。这一重要的融资事件不仅是对快招无忧公司团队专业能力和业务 模式的高度认可，更为快招无忧的未来发展注入了强劲的动力。让快招无忧更全面的帮组企业解决，招 商，财务合规，融资，上市等问题。 杭州快招无忧企业管理有限公司自18年成立以来，一直致力于为各类企业提供专业、高效、创新的管理 咨询服务。通过不断优化服务流程，已成功帮助上百家企业提升了运营效率，解决了企业资金的同时， 还帮组企 ...

Financial Data and Key Metrics Changes - Revenue increased by 5.9% year over year to $181.9 million, marking the highest quarterly revenue in the company's history [5] - Non-GAAP net income, earnings per diluted share, and EBITDA increased year over year by 11%, 13%, and 11% respectively, each setting a new quarterly record [6] - Consultant headcount decreased by 5% compared to the first quarter of fiscal 2024, remaining flat sequentially [7][18] - Consulting utilization improved year over year to 76% [7] Business Line Data and Key Metrics Changes - Four practices (energy, finance, intellectual property, and life sciences) posted double-digit revenue growth, while the antitrust and competition economics practice achieved a new high for quarterly revenue [6] - Revenue from legal and regulatory services increased by roughly 5%, aligning with broader legal market trends [9] - Management consulting services revenue increased by 10% year over year, driven by strong performance in energy and life sciences practices [13] Market Data and Key Metrics Changes - Worldwide M&A activity reached $885 billion during the first quarter of fiscal 2025, representing a 15% increase compared to the previous year [9] - Total case filings and court judgments increased by 132% compared to the first quarter of fiscal 2024 [9] Company Strategy and Development Direction - The company aims to optimize its service portfolio by reconfiguring teams in targeted areas, affecting approximately 15 individuals [16] - The company is focused on maintaining a strong pipeline of projects and is optimistic about the life sciences practice's growth potential [25][26] Management's Comments on Operating Environment and Future Outlook - Management noted that the journey to a record-setting Q1 was not linear, with a slow start in January followed by increased activity in February and March [23] - The company reaffirmed its full-year financial guidance for fiscal 2025, expecting revenue in the range of $715 million to $725 million and a non-GAAP EBITDA margin of 12% to 13% [17] Other Important Information - The company concluded the quarter with $25.6 million in cash and $85 million in borrowings under its revolving credit facility, resulting in net debt of $59.4 million [20] - The company will celebrate its sixtieth anniversary by ringing the opening bell for NASDAQ on June 2 [67] Q&A Session Summary Question: April activity and guidance confidence - Management observed that trends from March have continued into April, but it is too early to declare sustained success [24] Question: Life sciences pipeline opportunities - The life sciences practice is experiencing success geographically and across business concentration areas, with hopes for continued momentum [26] Question: Headcount growth and retention - The company is focused on optimizing investments and expects headcount growth to align with revenue growth in the medium to long term [30][32] Question: External factors affecting business activity - Management noted that various macro and geopolitical factors create uncertainty, impacting client decisions [41] Question: Industry verticals showing activity - All parts of the portfolio are growing, contributing to strong financial results [44] Question: Return to office trends - There has been no significant shift in office participation, with colleagues averaging just over three days a week in the office [47] Question: Restructuring details - The restructuring affected 15 individuals, aimed at optimizing the portfolio without indicating general health issues in the practices [56] Question: Antitrust demand trends - The antitrust and competition economics practice continues to see strong demand, driven by both merger-related activity and investigations [59] Question: Collaboration across practices - Collaboration across practices and geographies is common and is expected to grow as client needs become more complex [62]

Group 1 - The company held the ninth supervisory board meeting on April 27, 2025, where the profit distribution plan for 2024 was approved with 5 votes in favor, 0 abstentions, and 0 against [1] - The supervisory board believes the profit distribution plan complies with relevant laws and regulations, and it does not harm the interests of shareholders [1] - The profit distribution plan will be submitted to the shareholders' meeting for approval [1] Group 2 - The company announced the confirmation of daily related party transactions for 2024 and the expected transactions for 2025, which are deemed necessary for normal business operations [4][5] - The daily related party transactions are conducted under principles of openness, fairness, and justice, ensuring no adverse impact on the company's operations or minority shareholders [4][6] - The company is involved in a lawsuit regarding unpaid consulting management fees, with an appeal filed after an unfavorable first-instance judgment [4][12] Group 3 - The company announced a change in accounting policy based on the Ministry of Finance's new regulations, which will not have a significant impact on financial results or shareholder interests [15][21] - The new accounting policy will be implemented from January 1, 2024, and does not require shareholder meeting approval [15][20] Group 4 - The company reported a total of 40,271,908.77 yuan in asset impairment provisions for 2024, which positively impacted the consolidated profit for the year [27] - The company conducted impairment tests on various assets and made provisions based on prudence [24][25] Group 5 - The company plans to provide guarantees for its wholly-owned subsidiaries, with a total guarantee amount not exceeding 40 million yuan [32][35] - The guarantee is intended to support the subsidiaries' operational funding needs and will be submitted for shareholder approval [34][36] - The company has no overdue guarantees and the proposed guarantees are considered manageable risks [33][44] Group 6 - The company will hold its 2024 annual shareholders' meeting on May 20, 2025, with both on-site and online voting options available [49][50] - The meeting will address various proposals that have been previously approved by the board and supervisory committee [52][53]